-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Bjzy+cXfrEhwtpQlimeMVw1ExEz1+aYkOyouxMYfdqR0zOXm6Cz7RlggC7kBcAlW WthiXaJLmAsv5NwFKgCMoA== 0001341004-08-000821.txt : 20080501 0001341004-08-000821.hdr.sgml : 20080501 20080501172522 ACCESSION NUMBER: 0001341004-08-000821 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080501 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20080501 DATE AS OF CHANGE: 20080501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENDO PHARMACEUTICALS HOLDINGS INC CENTRAL INDEX KEY: 0001100962 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 134022871 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15989 FILM NUMBER: 08795761 BUSINESS ADDRESS: STREET 1: 100 ENDO BOULEVARD CITY: CHADDS FORD STATE: PA ZIP: 19317 BUSINESS PHONE: 6105589800 MAIL ADDRESS: STREET 1: 100 ENDO BOULEVARD CITY: CHADDS FORD STATE: PA ZIP: 19317 8-K 1 endo_8k.htm FORM 8-K endo_8k.htm

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
     
Date of Report (Date of Earliest Event Reported):
  
May 1, 2008 (April 29, 2008)

 
Endo Pharmaceuticals Holdings Inc.
_________________________________________
(Exact name of registrant as specified in its charter)
 
         
Delaware
  
001-15989
  
13-4022871
_____________________
(State or other jurisdiction
  
_____________
(Commission
  
______________
(I.R.S. Employer
of incorporation)
  
File Number)
  
Identification No.)
  
        
100 Endo Boulevard, Chadds Ford, PA
      
19317
_________________________________
(Address of principal executive offices)
      
___________
(Zip Code)

     
Registrant’s telephone number, including area code
  
(610) 558-9800
 
Not Applicable
_____________________________________________
Former name or former address, if changed since last report
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
Item 5.02 Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
 
On April 29, 2008, Michel de Rosen notified Endo Pharmaceuticals Holdings Inc. (the "Company") of his intent to not stand for reelection as a director of the Company at the Company's 2008 Annual Meeting of Stockholders so that he may devote more time to his new position as Chief Executive Officer of Saint-Gobain Desjonqueres in France, a position he has held since March 31, 2008.  Mr. de Rosen will continue to serve as a director of the Company until the expiration of his term at the Company's 2008 Annual Meeting of Stockholders.
 
 
On April 29, 2008, Dr. David A.H. Lee, M.D., Ph.D., notified the Company that he was resigning his position as Chief Scientific Officer, effective April 30, 2008, to devote more time to pursue his philanthropic activities.  Dr. Lee, who has been working part-time for the Company for over a year, has agreed at the Company’s request to remain with the Company as a senior strategic adviser primarily to continue to support the Company’s activities in the area of public affairs. 
 

 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.


 
ENDO PHARMACEUTICALS HOLDINGS INC.
       
       
 
By:
/s/ Caroline B. Manogue
  
   
Name:
Caroline B. Manogue
   
Title:
Executive Vice President, Chief Legal Officer & Secretary
       
       
       
       


Dated:  May 1, 2008

 -----END PRIVACY-ENHANCED MESSAGE-----